Vaxart (VXRT) Proxy filing summary

Executive summary

• Agreement reached with a group of shareholders to resolve a proxy contest, demonstrating a focus on corporate governance and shareholder engagement.

• Emphasis on advancing clinical, regulatory, and operational milestones, particularly in validating the oral vaccine platform.

• Board expresses confidence in leadership and strategy to deliver on upcoming opportunities.

Voting matters and shareholder proposals

• Shareholders are encouraged to vote, following the resolution of the proxy contest.

Board of directors and corporate governance

• Commitment to strong corporate governance highlighted by the resolution of the proxy contest.

• Board asserts its expertise and focus in guiding the company through upcoming milestones.